140 related articles for article (PubMed ID: 36995731)
21. Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups.
Gronchi A; Hindi N; Cruz J; Blay JY; Lopez-Pousa A; Italiano A; Alvarez R; Gutierrez A; Rincón I; Sangalli C; Pérez Aguiar JL; Romero J; Morosi C; Sunyach MP; Sanfilippo R; Romagosa C; Ranchere-Vince D; Dei Tos AP; Casali PG; Martin-Broto J
EClinicalMedicine; 2019 Mar; 9():35-43. PubMed ID: 31143880
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Demetri GD; Chawla SP; von Mehren M; Ritch P; Baker LH; Blay JY; Hande KR; Keohan ML; Samuels BL; Schuetze S; Lebedinsky C; Elsayed YA; Izquierdo MA; Gómez J; Park YC; Le Cesne A
J Clin Oncol; 2009 Sep; 27(25):4188-96. PubMed ID: 19652065
[TBL] [Abstract][Full Text] [Related]
23. A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma.
Assi T; Kattan J; El Rassy E; Honore C; Dumont S; Mir O; Le Cesne A
Cancer Treat Rev; 2019 Jan; 72():37-44. PubMed ID: 30468937
[TBL] [Abstract][Full Text] [Related]
24. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
25. Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
Jones RL; Herzog TJ; Patel SR; von Mehren M; Schuetze SM; Van Tine BA; Coleman RL; Knoblauch R; Triantos S; Hu P; Shalaby W; McGowan T; Monk BJ; Demetri GD
Cancer Med; 2021 Jun; 10(11):3565-3574. PubMed ID: 33960681
[TBL] [Abstract][Full Text] [Related]
26. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.
Taieb S; Saada-Bouzid E; Tresch E; Ryckewaert T; Bompas E; Italiano A; Guillemet C; Peugniez C; Piperno-Neumann S; Thyss A; Maynou C; Clisant S; Penel N;
Eur J Cancer; 2015 Jan; 51(2):202-9. PubMed ID: 25499439
[TBL] [Abstract][Full Text] [Related]
27. Complete response of a recurrent-metastatic liposarcoma with dedifferentiated histological features following the administration of trabectedin and review of literature.
Kus T; Aktas G; Kalender ME; Tutar E; Ulker E; Camci C
J Cancer Res Ther; 2015; 11(4):974-6. PubMed ID: 26881560
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.
Samuels BL; Chawla S; Patel S; von Mehren M; Hamm J; Kaiser PE; Schuetze S; Li J; Aymes A; Demetri GD
Ann Oncol; 2013 Jun; 24(6):1703-9. PubMed ID: 23385197
[TBL] [Abstract][Full Text] [Related]
29. Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age.
Hoiczyk M; Grabellus F; Podleska L; Ahrens M; Schwindenhammer B; Taeger G; Pöttgen C; Schuler M; Bauer S
Int J Oncol; 2013 Jul; 43(1):23-8. PubMed ID: 23652821
[TBL] [Abstract][Full Text] [Related]
30. Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).
Kasper B; Reichardt P; Pink D; Sommer M; Mathew M; Rauch G; Hohenberger P
Mar Drugs; 2015 Jan; 13(1):379-88. PubMed ID: 25591040
[TBL] [Abstract][Full Text] [Related]
31. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
[TBL] [Abstract][Full Text] [Related]
32. Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study.
Ohmoto A; Nakano K; Fukuda N; Wang X; Urasaki T; Hayashi N; Suto H; Udagawa S; Oki R; Sato Y; Yunokawa M; Ono M; Saito M; Minami Y; Hayakawa K; Tanizawa T; Ae K; Matsumoto S; Tomomatsu J; Takahashi S
PLoS One; 2023; 18(3):e0280508. PubMed ID: 36857355
[TBL] [Abstract][Full Text] [Related]
33. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.
Carter NJ; Keam SJ
Drugs; 2010 Feb; 70(3):355-76. PubMed ID: 20166769
[TBL] [Abstract][Full Text] [Related]
34. Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma.
de Sande González LM; Martin-Broto J; Kasper B; Blay JY; Le Cesne A
Expert Rev Anticancer Ther; 2020 Nov; 20(11):957-963. PubMed ID: 32930637
[TBL] [Abstract][Full Text] [Related]
35. Retrospective Analysis of Trabectedin Therapy for Soft Tissue Sarcoma.
Kawaguchi K; Nakano K; Urasaki T; Fukuda N; Taira S; Ono M; Tomomatsu J; Nishizawa M; Ae K; Matsumoto S; Takahashi S
In Vivo; 2019; 33(5):1609-1614. PubMed ID: 31471412
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of trabectedin for the treatment of liposarcoma.
Zijoo R; von Mehren M
Expert Opin Pharmacother; 2016 Oct; 17(14):1953-62. PubMed ID: 27615729
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity.
Canter RJ; Borys D; Olusanya A; Li CS; Lee LY; Boutin RD; Christensen SD; Tamurian RM; Monjazeb AM
Ann Surg Oncol; 2014 May; 21(5):1616-23. PubMed ID: 24554062
[TBL] [Abstract][Full Text] [Related]
38. Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1.
Dossi R; Frapolli R; Di Giandomenico S; Paracchini L; Bozzi F; Brich S; Castiglioni V; Borsotti P; Belotti D; Uboldi S; Sanfilippo R; Erba E; Giavazzi R; Marchini S; Pilotti S; D'Incalci M; Taraboletti G
Int J Cancer; 2015 Feb; 136(3):721-9. PubMed ID: 24917554
[TBL] [Abstract][Full Text] [Related]
39. Myxoid Liposarcomas: Systemic Treatment Options.
Nassif EF; Keung EZ; Thirasastr P; Somaiah N
Curr Treat Options Oncol; 2023 Apr; 24(4):274-291. PubMed ID: 36853469
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups.
Gronchi A; Palmerini E; Quagliuolo V; Martin Broto J; Lopez Pousa A; Grignani G; Brunello A; Blay JY; Tendero O; Diaz Beveridge R; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Braglia L; Donati DM; Palassini E; Bianchi G; Marrari A; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
J Clin Oncol; 2020 Jul; 38(19):2178-2186. PubMed ID: 32421444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]